Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free HNGE Stock Alerts

Hinge Health (HNGE) Financials

Hinge Health logo
$55.09 +1.21 (+2.25%)
As of 02:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Hinge Health

Annual Income Statements for Hinge Health

This table shows Hinge Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -108 -12 -424
Consolidated Net Income / (Loss)		 -108 -12 -528
Net Income / (Loss) Continuing Operations		 -108 -12 -528
Total Pre-Tax Income 		-109 -11 -527
Total Operating Income		 -131 -32 -546
Total Gross Profit		 194 300 468
Total Revenue		 293 390 588
Operating Revenue		 293 390 588
Total Cost of Revenue		 99 91 120
Operating Cost of Revenue		 99 91 120
Total Operating Expenses		 325 332 1,015
Selling, General & Admin Expense		 67 64 330
Marketing Expense		 148 167 317
Research & Development Expense		 110 101 368
Total Other Income / (Expense), net		 22 21 19
Other Income / (Expense), net		 - - 19
Income Tax Expense		 -0.41 0.68 1.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - -104
Basic Earnings per Share		 ($8.31) ($0.88) ($7.77)
Weighted Average Basic Shares Outstanding		 13.02M 13.56M 54.58M
Diluted Earnings per Share		 ($8.31) ($0.88) ($7.77)
Weighted Average Diluted Shares Outstanding		 13.02M 13.56M 54.58M
Weighted Average Basic & Diluted Shares Outstanding		 - - 78.76M

Quarterly Income Statements for Hinge Health

This table shows Hinge Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -13 0.07 121 -576 -1.84 34
Consolidated Net Income / (Loss)		 -13 0.34 17 -576 -1.84 35
Net Income / (Loss) Continuing Operations		 -13 0.34 17 -576 -1.84 35
Total Pre-Tax Income 		-13 1.45 18 -576 -1.64 36
Total Operating Income		 -18 -3.85 13 -581 -6.09 32
Total Gross Profit		 67 79 100 98 126 154
Total Revenue		 90 101 124 139 154 182
Operating Revenue		 90 101 124 139 154 182
Total Cost of Revenue		 23 21 24 41 28 28
Operating Cost of Revenue		 23 21 24 41 28 28
Total Operating Expenses		 84 83 87 678 132 122
Selling, General & Admin Expense		 14 15 17 251 37 23
Marketing Expense		 45 45 47 147 64 69
Research & Development Expense		 25 24 23 280 32 30
Total Other Income / (Expense), net		 4.99 5.30 5.00 4.69 4.46 3.87
Income Tax Expense		 0.36 1.11 1.00 -0.33 0.21 0.81
Net Income / (Loss) Attributable to Noncontrolling Interest		 - 0.27 0.00 - 0.00 1.12
Basic Earnings per Share		 ($0.96) $0.01 $7.91 ($13.10) ($0.02) $0.43
Weighted Average Basic Shares Outstanding		 13.53M 13.62M 15.33M 43.93M 78.86M 78.62M
Diluted Earnings per Share		 ($0.96) $0.01 $1.31 ($13.10) ($0.02) $0.41
Weighted Average Diluted Shares Outstanding		 13.53M 16.58M 92.75M 43.93M 78.86M 82.39M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 81.02M 81.30M 77.38M

Annual Cash Flow Statements for Hinge Health

This table details how cash moves in and out of Hinge Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -65 65 -93
Net Cash From Operating Activities		 -64 49 171
Net Cash From Continuing Operating Activities		 -64 49 171
Net Income / (Loss) Continuing Operations		 -108 -12 -528
Consolidated Net Income / (Loss)		 -108 -12 -528
Depreciation Expense		 5.63 5.95 5.13
Amortization Expense		 9.58 30 47
Non-Cash Adjustments To Reconcile Net Income		 20 12 650
Changes in Operating Assets and Liabilities, net		 8.94 13 -1.96
Net Cash From Investing Activities		 1.50 18 -114
Net Cash From Continuing Investing Activities		 1.50 18 -114
Purchase of Property, Plant & Equipment		 -4.62 -3.77 -6.06
Acquisitions		 0.00 0.00 -4.00
Purchase of Investments		 -453 -325 -472
Sale and/or Maturity of Investments		 459 347 369
Net Cash From Financing Activities		 -3.00 -2.20 -150
Net Cash From Continuing Financing Activities		 -3.00 -2.20 -150
Repayment of Debt		 0.00 0.00 4.93
Repurchase of Preferred Equity		 0.00 0.00 -50
Repurchase of Common Equity		 -0.65 -2.81 -75
Issuance of Common Equity		 0.00 0.00 264
Other Financing Activities, net		 -2.36 0.61 -294
Cash Income Taxes Paid		 0.00 0.00 1.56

Quarterly Cash Flow Statements for Hinge Health

This table details how cash moves in and out of Hinge Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q4 2024 Q1 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2024 12/31/2024 3/31/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 31 33 -12 24 -53 -22
Net Cash From Operating Activities		 28 38 4.93 82 64 43
Net Cash From Continuing Operating Activities		 28 38 4.93 82 64 43
Net Income / (Loss) Continuing Operations		 0.34 27 17 -1.84 32 35
Consolidated Net Income / (Loss)		 0.34 27 17 -1.84 32 35
Depreciation Expense		 1.42 1.37 1.30 1.26 1.22 1.17
Amortization Expense		 7.55 9.27 9.24 13 14 16
Non-Cash Adjustments To Reconcile Net Income		 2.53 2.35 1.74 36 18 13
Changes in Operating Assets and Liabilities, net		 17 -1.76 -24 34 -1.42 -22
Net Cash From Investing Activities		 2.53 -3.11 -21 -59 -38 48
Net Cash From Continuing Investing Activities		 2.53 -3.11 -21 -59 -38 48
Purchase of Property, Plant & Equipment		 -0.86 -1.03 -0.76 -1.12 -2.36 -1.53
Acquisitions		 - - -4.00 - - 0.00
Purchase of Investments		 -80 -83 -90 -143 -154 -59
Sale and/or Maturity of Investments		 84 81 74 85 119 109
Net Cash From Financing Activities		 -0.02 -2.34 4.10 0.53 -80 -113
Net Cash From Continuing Financing Activities		 -0.02 -2.34 4.10 0.53 -80 -113
Repayment of Debt		 - - 4.93 - - 0.00
Repurchase of Common Equity		 -0.14 -2.54 -0.93 - -65 -105
Other Financing Activities, net		 0.13 0.21 0.10 0.53 -22 -7.88
Cash Income Taxes Paid		 -0.21 - 0.00 1.01 0.35 0.50

Annual Balance Sheets for Hinge Health

This table presents Hinge Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2025
Period end date 12/31/2024 12/31/2025
Total Assets		 673 745
Total Current Assets		 583 534
Cash & Equivalents		 301 208
Short-Term Investments		 166 156
Accounts Receivable		 42 66
Inventories, net		 11 16
Prepaid Expenses		 45 57
Other Current Assets		 19 31
Plant, Property, & Equipment, net		 7.38 10
Total Noncurrent Assets		 82 200
Long-Term Investments		 0.00 113
Goodwill		 62 64
Intangible Assets		 1.81 2.51
Other Noncurrent Operating Assets		 19 21
Total Liabilities & Shareholders' Equity		 673 745
Total Liabilities		 257 366
Total Current Liabilities		 249 362
Accounts Payable		 28 57
Current Deferred Revenue		 218 301
Other Current Liabilities		 3.81 4.22
Total Noncurrent Liabilities		 7.26 3.82
Other Noncurrent Operating Liabilities		 7.26 3.82
Commitments & Contingencies		 0.00 0.00
Redeemable Noncontrolling Interest		 851 200
Total Equity & Noncontrolling Interests		 -435 179
Total Preferred & Common Equity		 -435 179
Total Common Equity		 -435 179
Common Stock		 88 1,230
Retained Earnings		 -523 -1,051
Accumulated Other Comprehensive Income / (Loss)		 0.07 -0.02

Quarterly Balance Sheets for Hinge Health

This table presents Hinge Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2025 9/30/2025 3/31/2026
Total Assets		 694 770 729
Total Current Assets		 598 659 540
Cash & Equivalents		 237 261 187
Short-Term Investments		 176 219 129
Accounts Receivable		 99 87 115
Inventories, net		 14 14 14
Prepaid Expenses		 48 49 61
Other Current Assets		 24 29 35
Plant, Property, & Equipment, net		 7.72 8.40 11
Total Noncurrent Assets		 88 103 177
Long-Term Investments		 - 15 90
Goodwill		 64 64 64
Intangible Assets		 2.96 2.74 2.29
Other Noncurrent Operating Assets		 20 21 21
Total Liabilities & Shareholders' Equity		 694 770 729
Total Liabilities		 320 362 417
Total Current Liabilities		 314 357 414
Accounts Payable		 35 53 69
Current Deferred Revenue		 275 300 341
Other Current Liabilities		 4.05 4.18 4.23
Total Noncurrent Liabilities		 5.92 4.85 2.74
Other Noncurrent Operating Liabilities		 5.92 4.85 2.74
Commitments & Contingencies		 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 200 200 200
Total Equity & Noncontrolling Interests		 174 208 112
Total Preferred & Common Equity		 174 208 112
Total Common Equity		 174 208 112
Common Stock		 1,255 1,291 1,128
Retained Earnings		 -1,081 -1,083 -1,016
Accumulated Other Comprehensive Income / (Loss)		 -0.03 0.05 -0.35

Annual Metrics And Ratios for Hinge Health

This table displays calculated financial ratios and metrics derived from Hinge Health's official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 81,301,251.00
DEI Adjusted Shares Outstanding		 0.00 0.00 81,301,251.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -5.22
Growth Metrics		 - - -
Profitability Metrics		 - - -
Net Operating Profit after Tax (NOPAT)		 -91 -22 -382
Return On Investment Capital (ROIC_SIMPLE)		 - 5.14% -214.07%
Earnings before Interest and Taxes (EBIT)		 -131 -32 -527
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -115 4.49 -475
Valuation Ratios		 - - -
Leverage & Solvency		 - - -
Liquidity Ratios		 - - -
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 28 -334
Efficiency Ratios		 - - -
Capital & Investment Metrics		 - - -
Invested Capital		 0.00 -50 -98
Increase / (Decrease) in Invested Capital		 0.00 -50 -49
Book Value per Share		 $0.00 ($32.05) $2.20
Tangible Book Value per Share		 $0.00 ($36.73) $1.38
Total Capital		 0.00 417 379
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 0.00 -467 -477
Capital Expenditures (CapEx)		 4.62 3.77 6.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -132 -192
Debt-free Net Working Capital (DFNWC)		 0.00 334 171
Net Working Capital (NWC)		 0.00 334 171
Net Nonoperating Expense (NNE)		 17 -10 146
Net Nonoperating Obligations (NNO)		 0.00 -467 -477
Total Depreciation and Amortization (D&A)		 15 36 52
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($7.77)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 54.58M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($7.77)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 54.58M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 78.76M
Normalized Net Operating Profit after Tax (NOPAT)		 -91 -22 -382
Debt Service Ratios		 - - -
Payout Ratios		 - - -

Quarterly Metrics And Ratios for Hinge Health

This table displays calculated financial ratios and metrics derived from Hinge Health's official financial filings.

Metric Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
DEI Shares Outstanding		 - - 0.00 - - 78,763,240.00
DEI Adjusted Shares Outstanding		 - - 0.00 - - 78,763,240.00
DEI Earnings Per Adjusted Shares Outstanding		 - - 0.00 - - 0.43
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 54.85% 53.27% 47.23%
EBITDA Growth		 0.00% 0.00% 0.00% -4,483.98% 17.53% 72.89%
EBIT Growth		 0.00% 0.00% 0.00% -4,483.98% -212.97% 76.82%
NOPAT Growth		 0.00% 0.00% 0.00% -3,208.48% -371.68% 152.48%
Net Income Growth		 0.00% 0.00% 0.00% -4,353.43% -640.76% 104.96%
EPS Growth		 0.00% 0.00% 0.00% -1,264.58% -300.00% -68.70%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% 190.15% 774.78%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 12.01% 0.00% 0.00% 10.87% 0.00%
EBITDA Q/Q Growth		 0.00% 182.90% 0.00% 0.00% 102.13% 0.00%
EBIT Q/Q Growth		 0.00% 111.54% 0.00% 0.00% 99.72% 0.00%
NOPAT Q/Q Growth		 0.00% 92.64% 0.00% 0.00% 98.95% 0.00%
Net Income Q/Q Growth		 0.00% 102.64% 0.00% 0.00% 99.68% 0.00%
EPS Q/Q Growth		 0.00% 101.04% 0.00% 0.00% 99.85% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -87.15% 0.00% 0.00% -32.57%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 122.62% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -120.26% 0.00%
Profitability Metrics		 - - - - - -
Gross Margin		 74.16% 78.77% 80.95% 70.28% 81.84% 84.60%
EBITDA Margin		 -13.99% 10.35% 23.16% -414.08% 7.94% 27.20%
Operating Margin		 -19.54% -3.82% 10.61% -417.45% -3.95% 17.59%
EBIT Margin		 -13.99% 1.44% 14.65% -414.08% -1.06% 17.59%
Profit (Net Income) Margin		 -14.39% 0.34% 13.84% -413.85% -1.20% 19.27%
Tax Burden Percent		 102.87% 23.52% 94.50% 99.94% 112.58% 97.74%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 112.08%
Effective Tax Rate		 0.00% 76.48% 5.50% 0.00% 0.00% 2.26%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% 0.00% 0.00% -163.78%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 15.60%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 17.09%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% 0.00% 0.00% -58.71%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -12 -0.90 12 -406 -4.27 31
NOPAT Margin		 -13.68% -0.90% 10.03% -292.22% -2.77% 17.19%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% -81.88% 0.98% 1.87%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -233.90% -2.05% 28.06%
Cost of Revenue to Revenue		 25.84% 21.23% 19.05% 29.72% 18.16% 15.40%
SG&A Expenses to Revenue		 15.98% 14.66% 13.63% 180.62% 23.90% 12.63%
R&D to Revenue		 27.74% 23.64% 18.98% 201.27% 20.70% 16.64%
Operating Expenses to Revenue		 93.70% 82.59% 70.34% 487.74% 85.79% 67.01%
Earnings before Interest and Taxes (EBIT)		 -13 1.45 18 -576 -1.64 32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 10 29 -576 12 50
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 13.08 18.61 28.45
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 21.30 27.42 70.13
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 4.92
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 4.60
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 14.18
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 0.00 0.00 -1.11 -1.21 -1.30
Leverage Ratio		 0.00 0.00 0.00 1.86 1.89 2.34
Compound Leverage Factor		 0.00 0.00 0.00 1.86 1.89 2.62
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 53.49% 49.00% 64.15%
Common Equity to Total Capital		 0.00% 0.00% 0.00% 46.51% 51.00% 35.85%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 0.00 0.00 3.86
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 64.15%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.00 0.00 0.00 1.91 1.85 1.30
Quick Ratio		 0.00 0.00 0.00 1.63 1.59 1.04
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 -367 83 125
Operating Cash Flow to CapEx		 0.00% 3,302.09% 650.59% 0.00% 7,376.72% 2,815.88%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.89
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 5.62
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 8.76
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 56.95
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 1.79
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 64.90
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 41.66
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 204.31
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 -97.75
Capital & Investment Metrics		 - - - - - -
Invested Capital		 0.00 0.00 0.00 -40 -87 -94
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 -13.74
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 -40 -87 -94
Enterprise Value (EV)		 0.00 0.00 0.00 2,060 3,575 2,971
Market Capitalization		 437 437 437 2,273 3,870 3,177
Book Value per Share		 $0.00 $0.00 $0.00 $3.96 $2.57 $1.42
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $2.43 $1.74 $0.58
Total Capital		 0.00 0.00 0.00 374 408 312
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 0.00 0.00 -413 -495 -406
Capital Expenditures (CapEx)		 0.00 0.86 0.76 0.00 1.12 1.53
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 -129 -178 -190
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 284 302 126
Net Working Capital (NWC)		 0.00 0.00 0.00 284 302 126
Net Nonoperating Expense (NNE)		 0.64 -1.25 -4.72 169 -2.42 -3.79
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -413 -495 -406
Total Depreciation and Amortization (D&A)		 0.00 8.97 11 0.00 14 18
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -29.44%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 19.43%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 19.43%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($13.10) ($0.02) $0.43
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 43.93M 78.86M 78.62M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($13.10) ($0.02) $0.41
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 43.93M 78.86M 82.39M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 81.02M 81.30M 77.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -2.69 12 -406 -4.27 31
Normalized NOPAT Margin		 -13.68% -2.68% 10.03% -292.22% -2.77% 17.19%
Pre Tax Income Margin		 -13.99% 1.44% 14.65% -414.08% -1.06% 19.72%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -35.16%

Financials Breakdown Chart

Key Financial Trends

  • Q4 2025: Consolidated Net Income / (Loss) and Net Income / (Loss) Continuing Operations were positive at about $32.10 million, marking a rebound from the losses seen in the preceding quarters.
  • Revenue trend in 2025 shows growth: Q3 2025 Operating Revenue / Total Revenue reached $154.211 million, up from $139.098 million in Q2 2025 and well above $100.615 million in Q3 2024.
  • Gross-margin improvement in Q3 2025: Total Gross Profit was $126.199 million on $154.211 million of revenue, roughly an 81.7% gross margin, up from about 70.3% in Q2 2025.
  • Operating cash flow remained positive in the latest quarter: Net Cash From Continuing Operating Activities was $63.893 million in Q4 2025, supported by substantial non-cash adjustments.
  • Liquidity position appears solid: Cash & Equivalents of $261.342 million and Short-Term Investments of $218.685 million as of Q3 2025, with Total Current Assets of $658.882 million.
  • Redeemable Noncontrolling Interest was about $199.874 million in Q3 2025, a sizeable non-operating equity-related item that adds complexity to capitalization.
  • Current Deferred Revenue remained high in 2025 (about $275.1 million in Q2 2025 and $299.7 million in Q3 2025), indicating substantial upfront bookings that could reverse in future periods.
  • Total equity rose from $173.8 million in Q2 2025 to about $208.0 million in Q3 2025, signaling an improvement in capitalization (positive trend but still a work-in-progress given earnings volatility).
  • Q2 2025 Net Income / Continuing Operations declined sharply to about -$575.65 million, highlighting a substantial quarterly loss.
  • Q3 2025 Net Income / Continuing Operations remained negative at approximately -$1.844 million, underscoring ongoing profitability challenges despite the revenue growth.
05/15/26 12:27 PM ETAI Generated. May Contain Errors.

Hinge Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Hinge Health's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Hinge Health's net income appears to be on an upward trend, with a most recent value of -$528.26 million in 2025, rising from -$108.14 million in 2023. The previous period was -$11.93 million in 2024. Check out Hinge Health's forecast to explore projected trends and price targets.

Hinge Health's total operating income in 2025 was -$546.37 million, based on the following breakdown:
  • Total Gross Profit: $468.22 million
  • Total Operating Expenses: $1.01 billion

Over the last 2 years, Hinge Health's total revenue changed from $292.73 million in 2023 to $587.86 million in 2025, a change of 100.8%.

Hinge Health's total liabilities were at $366.23 million at the end of 2025, a 42.7% increase from 2024, and a 42.7% increase since 2024.

In the past 1 years, Hinge Health's cash and equivalents has ranged from $208.00 million in 2025 to $300.79 million in 2024, and is currently $208.00 million as of their latest financial filing in 2025.

Over the last 2 years, Hinge Health's book value per share changed from 0.00 in 2023 to 2.20 in 2025, a change of 219.8%.


Related Companies

Financial statements for NYSE:HNGE last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel